Physician profile
Mark P Bryer
NPI 1144217324
$15,262.92
in general payments reported to CMS, 2019-2025
76 companies · $3,147 in 2025
The $3,147 reported for 2025 was more than what 93% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,339 · 2020: $1,004 · 2021: $1,242 · 2022: $2,386 · 2023: $2,994 · 2024: $3,151 · 2025: $3,147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,224 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,224.00 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $2,078.34 | 2019-2025 | Optune, Optune Gio |
| Janssen Biotech, INC. | $1,649.47 | 2019-2025 | Darzalex, Talvey, Tecvayli |
| Novartis Pharmaceuticals Corporation | $1,120.11 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,089.74 | 2019-2025 | Imfinzi, Lynparza, Enhertu |
| Merck Sharp & Dohme LLC | $718.32 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $716.49 | 2019-2025 | |
| Gt Medical Technologies, INC | $698.68 | 2022-2025 | Gammatile, Gammatile |
| Seagen INC. | $575.24 | 2019-2023 | Tukysa, Adcetris, Padcev |
| Incyte Corporation | $534.76 | 2019-2025 | Monjuvi, Pemazyre, Jakafi |
| Eisai INC. | $423.48 | 2020-2025 | |
| Daiichi Sankyo INC. | $396.24 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Amgen INC. | $350.20 | 2019-2023 | Xgeva, Vectibix, Nplate |
| Abbvie INC. | $334.13 | 2019-2025 | Venclexta |
| Pharmacyclics LLC, An Abbvie Company | $312.13 | 2019-2023 | Imbruvica, Epkinly |
| Emd Serono, INC. | $270.07 | 2019-2025 | Bavencio |
Show all 76 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Bryer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.